08.03.2026
Biocon Launches Aflibercept Biosimilar Yesafili in the US
Biocon announced the commercial launch of Yesafili (aflibercept-jbvf) in the United States, expanding the availability of an interchangeable biosimilar to Eylea (aflibercept) 2 mg for the treatment of retinal vascular diseases. The FDA approved Yesafili in May 2024 and granted the product interchangeable designation, allowing pharmacy-level substitution for the reference product.